O
Oculis Holding AG
NASDAQ:OCS
Oculis Holding AG
NASDAQ:OCS
Price:
26.42
USD
-1.86%
Market Cap:
$1.5B
Relative Value
The Relative Value of one OCS stock under the Base Case scenario is 23.01 USD. Compared to the current market price of 26.42 USD, Oculis Holding AG is Overvalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OCS
Relative Value
Base Case
23.01
USD
Overvaluation 13%
O
Multiples Across Competitors
OCS Competitors Multiples
Oculis Holding AG Competitors
Oculis Holding AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
O
|
Oculis Holding AG
NASDAQ:OCS
|
1.6B USD | 0 | -12.4 | -14.1 | -14 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.2 | 41.7 | 28.2 | 30.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.5 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224B GBP | 5 | 28.8 | 16 | 22.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
